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DOI 10.1016/j.ccr.2011.12.028SUMMARYEsophageal adenocarcinoma (EAC) is the most prevalent esophageal cancer type in the United States. The
TNF-a/mTOR pathway is known tomediate the development of EAC. Additionally, aberrant activation of Gli1,
downstream effector of the Hedgehog (HH) pathway, has been observed in EAC. In this study, we found that
an activated mTOR/S6K1 pathway promotes Gli1 transcriptional activity and oncogenic function through
S6K1-mediated Gli1 phosphorylation at Ser84, which releases Gli1 from its endogenous inhibitor, SuFu.
Moreover, elimination of S6K1 activation by an mTOR pathway inhibitor enhances the killing effects of the
HH pathway inhibitor. Together, our results established a crosstalk between the mTOR/S6K1 and HH path-
ways, which provides amechanism for SMO-independent Gli1 activation and also a rationale for combination
therapy for EAC.INTRODUCTION
Esophageal adenocarcinoma (EAC) is one of the most aggres-
sive cancers in the world, characterized by high mortality and
poor prognosis (Jemal et al., 2009). In the United States, EAC
has increased at a frequency of 5%–10% per year since theSignificance
The Hedgehog pathway plays a crucial role in many types o
mediator of canonical Hedgehog pathway, are being tested in
have shown potential efficacy, the development of resistan
mTOR/S6K1 directly activates Gli1 independent of SMO, which
SMO. However, an mTOR inhibitor could enhance the inhibitor
combination of the inhibitors against the mTOR/S6K1 and H
therapy.
374 Cancer Cell 21, 374–387, March 20, 2012 ª2012 Elsevier Inc.1980s, making it the fastest growing malignancy (Jemal et al.,
2009). Despite multidisciplinary therapeutic approaches, EAC
remains a virulent disease with an overall five-year survival
rate <20% (Hongo et al., 2009). It is very urgent to identify ther-
apeutic targets for prevention and establish biomarkers useful
for early detection of high-risk populations. Esophageal chronicf cancers, and several chemicals targeting SMO, the key
clinical trials for cancer therapy. Although these chemicals
ce has been also observed. Our data demonstrate that
results in the resistance of tumor cells to inhibitors targeting
y effects of SMO inhibitors on the tumor cells. Therefore, the
edgehog pathways may be more effective in cancer target
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S6K1-Mediated Activation of Gli1inflammation induced by gastro-esophageal reflux disease is an
important factor contributing to EAC (Lambert and Hainaut,
2007a, 2007b), and some inflammation-related cytokines have
been found to play pivotal roles in the development of EAC,
especially tumor necrosis factor (TNF)-a (Eksteen et al., 2001).
Our previous work has shown that TNF-a activates the mTOR
pathway through IKKb to stimulate the development and
progression of EAC (Yen et al., 2008). The mechanistic target
of rapamycin (mTOR) is a serine/threonine protein kinase, and
its activation leads to the phosphorylation of S6K1 and 4E-BP1
(Guertin and Sabatini, 2007). S6K1 is also a serine/threonine
kinase, and its phosphorylation by mTOR activates its function
to promote the mRNA translation of target genes (Guertin and
Sabatini, 2007). For 4E-BP1, however, phosphorylation by
mTOR inactivates its function and de-represses its inhibition
on cap-dependent translation (Guertin and Sabatini, 2007). The
mTOR pathway has been established pivotally to be involved
in many aspects of molecular and cellular biology, including
mRNA translation, ribosome biogenesis, cell growth and
survival, nutrient metabolism, immunosuppression, and aging,
as well as cancers (Guertin and Sabatini, 2007). Moreover, the
mTOR pathway is activated by TNF-a to promote angiogenesis
(Lee et al., 2007a), which facilitates the chronic inflammation-
induced cancers, including breast cancers (Lee et al., 2007a)
and esophageal cancers (EC; Hildebrandt et al., 2009; Yen
et al., 2008).
The Hedgehog (HH) signal pathway is also considered to be
crucially involved in the development of esophageal cancers
because it is overactivated and correlated with lymph node
metastasis (Katoh and Katoh, 2009a; Lee et al., 2009). The HH
pathway was identified first in Drosophila as an important regu-
lator for proper embryonic patterning and is highly conserved
from Drosophila to mammals (Ingham and McMahon, 2001).
Three HH ligands have been identified in mammals: Sonic
Hedgehog (SHH), Indian Hedgehog (IHH), and Desert Hedgehog
(DHH; Ng and Curran, 2011), which are secreted and initiate
signaling in receiving cells by binding and inactivating the HH
receptor Patched 1 (PTCH1). Inhibition of PTCH1 releases the
G-coupled receptor-like signal transducer Smoothened (SMO).
SMO then activates glioma-associated oncogenes (Gli) through
blocking their inhibitory partner, suppressor of fused (SuFu; Ng
and Curran, 2011). Gli proteins, including Gli1, 2, and 3, are
zinc finger transcription factors. Activated Gli proteins translo-
cate into the nucleus and stimulate the transcription of HH
pathway target genes, including Gli1, PTCH1, and many
survival-promoting molecules (Jiang and Hui, 2008; Ng and
Curran, 2011). Besides being activated by HH ligands-PTCH1-
SMO axis, also known as the canonical HH pathway (Jenkins,
2009), Gli proteins, mainly Gli1, have been reported to be acti-
vated by AKT (Katoh and Katoh, 2009b; Stecca et al., 2007),
MAPK/ERK (Seto et al., 2009), and KRAS (Nolan-Stevaux
et al., 2009) in HH ligands-PTCH1-SMO axis-independent or
SMO-independent manner (Ng and Curran, 2011). Although
the canonical pathway has been well established, how Gli1 is
regulated in a SMO-independent manner is still a puzzle.
Although bothmTOR andHH pathways have been considered
as drug targets in gastrointestinal (GI) cancer, including esopha-
geal cancers (Wiedmann and Caca, 2005), the correlation
between the two pathways has not been yet reported. Addition-ally, whether there is a relationship between TNF-a and HH
pathway in EAC is also not clear. Therefore, in this work, we
explored whether the TNF-a/mTOR pathway is involved in the
activation of the HH pathway in EAC.
RESULTS
TNF-a Promotes Gli1 Activity through the mTOR
Pathway
Because Gli protein activity is a useful readout for the HH
pathway (Jiang and Hui, 2008), we employed a Gli-dependent
luciferase reporter system (Sasaki et al., 1997) to evaluate the
influence of TNF-a on the HH pathway in three EAC cell lines:
BE3, SKGT-4, and OE33 (Boonstra et al., 2010). We observed
that TNF-a increases the expression of the reporter (Figure 1A)
and the mRNA levels of four Gli target genes (Figure 1B). There-
fore, TNF-a can activate the HH pathway in the EAC cells. Then,
we compared the activity of HH pathway in EAC cells stimulated
by SHHor TNF-a.We found that there is constitutive activation of
HH pathway in EAC cell lines, which can be inhibited by SMO
inhibitors, cyclopamine and GDC-0449 (Scales and de Sauvage,
2009). Both SHH and TNF-a increased the activity of HH
pathway in EAC cells with higher intensity from SHH (Figure S1A
available online).
To investigate whether TNF-a induces Gli activity through
SMO-dependent HH pathway, we pretreated the EAC cells
with cyclopamine followed by TNF-a. Interestingly, cyclopamine
did not affect the TNF-a-induced Gli activity (Figure 1C). Simi-
larly, knock-down of SMO did not inhibit the TNF-a-induced
Gli activity (Figure S1B). Therefore, TNF-a activates Gli function
in a SMO-independent manner. To determinewhether themTOR
pathway is involved in the regulation of Gli function by TNF-a, we
used rapamycin and WYE-354 to block the mTOR pathway
(Richard et al., 2010). Surprisingly, both compounds impaired
TNF-a-stimulated Gli activation (Figures 1C and S1C). Therefore,
TNF-a-stimulated Gli activation might require the activation
of mTOR pathway. To further evaluate this possibility, we over-
expressed wild-type mTOR or a rapamycin-resistant mTOR
(mTORS2035T; Brown et al., 1995) in EAC cells followed by
treatment of TNF-a alone or plus rapamycin.Western blot results
confirmed that rapamycin blocked activation of mTOR pathway
in mTOR-overexpressed cells but not in mTORS2035T-overex-
pressed cells (Figure S1D). Consistently, rapamycin suppressed
the TNF-a-stimulated Gli reporter expression in mTOR-trans-
fected EAC cells but barely had effect on mTORS2035T-trans-
fected EAC cells (Figure 1F). Collectively, these results suggest
that TNF-a activates Gli proteins through mTOR pathway.
Although Gli1, Gli2, and Gli3 all can regulate the expression of
the Gli reporter (Jiang and Hui, 2008; Ng and Curran, 2011), only
Gli1 knock-down impaired the TNF-a-stimulated expression of
Gli reporter (Figure S1E), which suggests that TNF-a selectively
activated Gli1. Consistently, TNF-a treatment rapidly induced
Gli1 nuclear accumulation without obvious changes in the total
protein level of Gli1 (Figure 1D, top panel). Rapamycin (Figure 1D,
middle panel), but not cyclopamine (Figure 1D, bottom panel),
blocked TNF-a-induced Gli1 nuclear accumulation, which was
further supported by the immunofluorescence staining (Figures
1E, S1F, and S1G). Therefore, TNF-a promotes Gli1 nuclear
localization and activation through the mTOR pathway.Cancer Cell 21, 374–387, March 20, 2012 ª2012 Elsevier Inc. 375
Figure 1. TNF-a Regulates Gli1 Transcriptional Activity
(A) Luciferase assay for Gli transcriptional activity in esophageal adenocarcinoma (EAC) cell lines with or without TNF-a (5 ng/ml) stimulation. The EAC cells were
transfected usingGliBS-Lucferase ormGliBS-Luciferasewith CMV-Renilla at a 10:1 ratio, serum-starved overnight, and then treatedwith TNF-a for 24 hr. GliBS is
Gli-responsive reporter, and mGliBS is Gli-unresponsive reporter. Error bars represent SD (n = 5).
(B) The mRNA levels of Gli1 target genes in the EAC cell lines with or without TNF-a (5 ng/ml) stimulation were examined by real-time PCR and normalized to the
mRNA level of ACTIN. Error bars represent SD (n = 4).
(C) EAC cells were cotreated with TNF-a (5 ng/ml) and cyclopamine (Cyc; 0.5, 1, and 5 mM) or TNF-a (5 ng/ml) and rapamycin (Rapa; 10, 50, and 100 nM) for 24 hr
and then subjected to luciferase assay. Error bars represent SD (n = 5 for cyclopamine treatment and n = 4 for rapamycin treatment).
(D) BE3 cells were treated with TNF-a (5 ng/ml) alone (top panel) or cotreated with TNF-a and rapamycin (50 nM, middle panel) or cyclopamine (1 mM, bottom
panel) for indicated time course. Then, the cells were lysed for cell fractionation followed by western blotting. Lamin B and tubulin were used as markers for the
nucleus and the cytoplasm, respectively.
(E) Immunofluorescent analysis of Gli1 in BE3 cells treated with TNF-a (5 ng/ml) alone or cotreated with TNF-a and rapamycin (50 nM). Scale bar = 100 mm for
original picture and 25 mm for inset. Dapi was used to stain nuclei.
(F) Luciferase assay for Gli reporter using BE3 cells transfected with wild-type mTOR or rapamycin-resistant mTOR (mTORS2035T) followed by treatment of
TNF-a alone or in combination with rapamycin (50 nM). Error bars represent SD (n = 4).
See also Figure S1.
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Figure 2. S6K1 Mediates the Regulation of Gli1 by TNF-a
(A) BE3 or SKGT4 cells were treated with TNF-a (5 ng/ml) alone or cotreated with TNF-a and rapamycin (50 nM) for 6 hr, and then the cells were lysed and
subjected to IP-western blot assay to examine the interactions between mTOR pathway components with Gli1.
(B) BE3 cells were transiently transfected with HA-tagged wild-type S6K1 (HA-S6K1), constitutively activated S6K1T389E (HA-T389E), function-loss S6K1T389A
(HA-T389A), or empty vector (EV). After 24 hr of the transfection, the cells were treated with or without rapamycin (100 nM) for additional 6 hr followed by lysis and
IP-western assay to test the interaction between S6K1 variants and Gli1. Phosphorylated S6 (p-S6) was used as marker for S6K1 activation.
(C) BE3 cells were transiently transfected with Gli-firefly and CMV-renilla reporters in combination with HA-S6K1, HA-T389E, HA-T389A, or EV. After 24 hr of the
transfection, the cells were treated with or without rapamycin (100 nM) for additional 24 hr followed by luciferase assay to measure the expression of Gli reporter.
Error bars represent SD (n = 3).
(D) The mRNA levels of Gli1 target genes in the BE3 cells transiently transfected with HA-S6K1, HA-T389E, HA-T389A, or EV followed by treatment with or
without rapamycin (100 nM)measured via real-time PCR. ThemRNA levels of Gli1 target genes were normalized to themRNA level of ACTIN. Error bars represent
SD (n = 3).
(E) Western blot analysis using the EAC cells transfected with control siRNA (Ctrl) or siRNA targeting S6K1 followed by TNF-a treatment.
(F) EAC cells were transiently transfected with control siRNA (Ctrl) or siRNA targeting S6K1. After 48 hr of the transfection, the cells were further transfected with
Gli-firefly and CMV-renilla reporters with or without TNF-a for additional 24 hr followed by luciferase assay. Error bars represent SD (n = 3).
(G) BE3 cells were transiently transfected with control siRNA (Ctrl) or siRNA targeting S6K1 followed by treatment with TNF-a or only treated with TNF-a. The
mRNA levels of Gli1 target genes in these cells were measured respectively through real-time PCR and normalized to the mRNA level of ACTIN. Error bars
represent SD (n = 3).
See also Figure S2.
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S6K1-Mediated Activation of Gli1S6K1 Mediates the Regulation of Gli1 by TNF-a
To investigate how themTOR pathway activates Gli1 activity, we
examined whether Gli1 interacts with the components of mTOR
pathway. Without TNF-a, no interactions were found betweenGli1 and mTOR pathway components; with TNF-a stimulation,
however, a clear interaction was observed between Gli1 and
S6K1 but not between Gli1 and mTOR or 4EB-P1 (Figures 2A
and S2A). Since Gli1 function is inhibited by SuFu, we alsoCancer Cell 21, 374–387, March 20, 2012 ª2012 Elsevier Inc. 377
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S6K1-Mediated Activation of Gli1examined whether there are any interactions between the mTOR
pathway components and SuFu. Unlike Gli1, SuFu did not
interact withmTOR, S6K1, or 4EB-P1, regardless of TNF-a treat-
ment (Figure S2B). Moreover, neither Gli2 nor Gli3 bound to
mTOR, S6K1, or 4EB-P1 (Figures S2C and S2D). Taken together,
the mTOR pathway might regulate Gli1 via S6K1.
Because S6K1 bound to Gli1 only under TNF-a stimulation,
we hypothesized that S6K1 might need to be activated to
interact with Gli1. To address this point, wild-type S6K1, consti-
tutively activated S6K1 (S6K1T389E), or function-loss S6K1
(S6K1T389A; Holz et al., 2005) was transfected into the BE3
cells. S6K1 and S6K1T389E increased S6K1 activity, as indi-
cated by increase of phosphorylation of S6, a substrate of
S6K1 (Figure 2B). Rapamycin could inhibit the activity of S6K1,
but not S6K1T389E (Figure 2B; Holz et al., 2005). Both S6K1
and S6K1T389E interacted with Gli1, and rapamycin effectively
inhibited the interaction between S6K1 and Gli1, but not
between S6K1T389E and Gli1 (Figure 2B). In addition, ectopic
expression of S6K1T389A did not interact with Gli1 (Figure 2B).
Furthermore, ectopic expression of S6K1 or S6K1T389E, but
not S6K1T389A, increased the expression of Gli reporter and
Gli1 target genes (Figures 2C and 2D). Rapamycin blocked the
effects of S6K1 on Gli reporter expression but did not affect
that of S6K1T389E (Figures 2C and 2D). Thus, only the activated
S6K1 formed complex with Gli1 and enhanced its activity.
To investigate whether S6K1mediates the regulation of Gli1 by
TNF-a, we knocked down S6K1 (Figure 2E) and tested the
regulation of Gli1 by TNF-a. The results indicated that the TNF-
a-stimulated Gli1 activity and expression of Gli target genes
were impeded by S6K1 knock-down (Figures 2F and 2G). Addi-
tionally, the inhibition of TNF-a-stimulated Gli1 activation by
siRNA, which targeted 30UTR region of S6K1 mRNA, was
rescued by expression of an exogenous S6K1 lacking of 30UTRs
but not by expression of exogenous S6K1T389A or a kinase-
dead S6K1 (S6K1 K100R; Holz et al., 2005; Figures S2E and
S2F). Therefore, activated S6K1 is required for the regulation of
Gli1 by the TNF-a/mTOR pathway.
Gli1 Is Phosphorylated by S6K1 and Required
for TNF-a/mTOR/S6K1-Mediated Cell Proliferation
Since S6K1 is a serine/threonine kinase, we askedwhether S6K1
regulates Gli1 through phosphorylation. Indeed, serine/threo-
nine phosphorylation of Gli1 was observed with the ectopic
expression of S6K1 or S6K1T389E (Figure 3A) but not of
S6K1T389A or S6K1K100R (Figure 3A). Furthermore, an
in vitro kinase assay showed that only the Gli1 fragment contain-
ing 1-500aa, Gli1F1, was phosphorylated by S6K1 but not by
S6K1K100R (Figure 3B). The phosphorylation level of Gli1F1
fragment is comparable to that of S6, suggesting that Gli1
was a substrate of S6K1 in vitro. We identified 79-KKRALS-84
(Figure S3A), which is highly conserved from fruit fly to
human (Figure 3C), as one potential S6K1-recognizing motif
(K/RxRxxS/T) in Gli1F1. When Ser84 was mutated to alanine
(Gli1S84A), phosphorylation of Gli1 by S6K1 disappeared (Fig-
ure 3D), suggesting that the Ser84 in Gli1 is the site phosphory-
lated by S6K1 in vitro.
To assess whether this phosphorylation occurs in vivo, we
performed mass spectrometric analysis using BE3 cells treated
with TNF-a alone or TNF-a and rapamycin. The results showed378 Cancer Cell 21, 374–387, March 20, 2012 ª2012 Elsevier Inc.that the phosphorylation of Gli1 Ser84 was detected in cells
treated with TNF-a but not in cells treated with rapamycin and
TNF-a (Figure S3B). Thus, the activation of the mTOR/S6K1
pathway contributes to the phosphorylation of Gli1 Ser84. To
further investigate endogenous Gli1 phosphorylation by TNF-a
or S6K1, we developed amouse polyclonal antibody that specif-
ically recognizes phosphorylated Ser84 of Gli1 (p-Gli1S84). This
antibody recognized TNF-a-stimulated flag-Gli1 but not without
TNF-a or flag-Gli1S84A, regardless of TNF-a treatment (Fig-
ure S3C). Using this antibody, we found that TNF-a stimulation
or S6K1 ectopic expression effectively induced Gli1 Ser84 phos-
phorylation (Figure 3E), which was diminished by the addition of
rapamycin (Figure 3E). Notably, phosphorylated Gli1 was
observed mainly in the nucleus (Figure 3F), which implied that
the phosphorylated Gli1 might be functionally activated. The
TNF-a-stimulated phosphorylation of Gli1 was largely inhibited
when S6K1 was knocked down by siRNA targeting 30UTR but
could be effectively rescued by exogenous S6K1 (Figure 3G).
Together, the results suggest that S6K1 mediates the regulation
of Gli1 by the TNF-a/mTOR pathway through phosphorylating
Gli1 at Ser84.
We also investigated if Gli1 activation is required for the effects
of the TNF-a/mTOR/S6K1 pathway on cellular oncogenecity. We
detected clear signals of p-Gli1S84 in BE3 and OE33 (Fig-
ure S3D), and knock-down of Gli1 impaired the TNF-a-stimu-
lated, as well as S6K1 ectopic, expression-increased cell
viability, proliferation, and invasion (Figures S3E and S3F).
Thus, the activation of Gli1 by S6K1 is functionally involved in
the TNF-a/mTOR pathway.
Besides TNF-a, we tested whether other mTOR pathway stim-
ulators led toGli1 phosphorylation. Amino acids also induced the
phosphorylation of Gli1S84 in BE3 cells (Figure S3H). Further-
more, the phosphorylation of Gli1S84 in TSC2/ MEFs, which
has constitutive activation of the mTOR pathway and S6K1, is
increased compared with TSC+/+ MEFs (Figure S3G). Therefore,
the activation of themTORpathway is an important stimulator for
Gli1 phosphorylation in both cancer and noncancerous cells.
The mTOR pathway includes two complexes. The first is
mTOR complex 1 (mTORC1), which requires raptor and acti-
vates S6K1, and the second is mTORC2, which requires rictor
and activates AKT (Zoncu et al., 2011). Rapamycin and WYE-
354 inhibit both mTORC1 and mTORC2 (Richard et al., 2010).
Therefore, we asked whether mTORC2 also regulates Gli1 phos-
phorylation. Although knock-down of mTOR or raptor impaired
the TNF-a-mediated Gli1 phosphorylation and activation,
knock-down of rictor did not (Figures 3H and S3I), indicating
that only mTORC1 plays a role in the regulation of Gli1.
Gli1 Phosphorylation by S6K1 Augments the Gli1
Function and Inhibits SuFu Binding
Since Gli1 is regulated by S6K1 in EAC cells, we wanted to know
if Gli1 is required for EAC transformation. We established BE3
stable clones with Gli1 knock-down (Figure 4A), and as ex-
pected, transcription of Gli1 target genes decreased with Gli1
knock-down (Figure 4B). Moreover, Gli1 knock-down also
decreased cell proliferation (Figures 4C and 4D), migration (Fig-
ure S4A), invasion (Figure S4B), and anchorage-independent
growth ability (Figure S4C). Thus, Gli1 is functionally required
for EAC cells. Then, to understand the effects of Ser84
Figure 3. S6K1 Phosphorylates Gli1 at Ser84
(A) The empty vector, wild-type S6K1, S6K1T389E, S6K1T389A, or kinase-dead S6K1 (S6K1K100R) was introduced into the BE3 cells, and endogenous Gli1 was
immunoprecipitated for western blot analysis. The phosphorylation was examined using anti-phospho-serine/threonine antibody.
(B) In vitro kinase assay using purified Gli1 fragment, containing 1–500 amino acids (Gli1F1), or Gli1F2, containing amino acid 501 to the end, plus purified wild-
type S6K1 kinase or kinase-dead S6K1 (S6K1KD). Arrowheads 1 and 4 show phosphorylated Gli1F1 detected using anti-phospho-serine/threonine antibody;
arrowheads 2 and 5 are purified Gli1F1 protein; and arrowhead 3 is purified Gli1F2 protein. The phosphorylation of S6 acts as a positive control.
(C) The S6K1 recognizing motif in Gli1 from fruit fly to human.
(D) In vitro kinase assay using purified Gli1F1 or Gli1F1 with the alanine substitution of serine 84 (S84A) plus purified S6K1.
(E)With the absence or presence of rapamycin (100 nM), BE3 cells were transiently transfectedwith S6K1 expression plasmid or treatedwith TNF-a (5 ng/ml). The
phosphorylation of Gli1S84 was detected using phosphor-Gli1S84-specific antibody in western blot analysis.
(F) BE3 cells were treated with TNF-a (5 ng/ml) for 6 hr, and then the cells were lysed for cell fractionation and subsequent western blot analysis. The phos-
phorylation of Gli1S84 was detected using phosphor-Gli1S84-specific antibody. Lamin B and tubulin were used as markers for the nucleus and cytoplasm,
respectively.
(G) BE3 cells were treated with TNF-a alone, or TNF-a plus siRNA targeting S6K1mRNA 30UTRwith or without transfection of S6K1 expression plasmid, and then
the cells were lysed for western blot analysis.
(H) Western blot analysis of BE3 cells transfected with control siRNA, or siRNA targeting mTOR, raptor, and rictor, respectively.
See also Figure S3.
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Figure 4. Knock-Down of Gli1 in EAC Cells
Decreases Cell Proliferation, Migration, Invasion,
and Colony Formation
(A) The BE3 stable clones with Gli1 knock-down. C, non-
silencing control shRNA; #1–5, five different Gli1 shRNAs.
(B) The mRNA levels of Gli1 target genes in the BE3 stable
clones with Gli1 knock-down measured via real-time PCR
and normalized to the mRNA level of ACTIN. Error bars
represent SD (n = 3).
(C) Cell counting analysis of the BE3 stable clones
with Gli1 knock-down. All cells were counted, and then
1 3 105 cells were seeded in 10 cm dishes. Error bars
represent SD (n = 3).
(D) MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide) assay of the BE3 stable clones with
Gli1 knock-down. All cells were counted, and then
3,000 cells were seeded in each well of a 96-well plate.
Error bars represent SD (n = 3).
See also Figure S4.
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S6K1-Mediated Activation of Gli1phosphorylation on Gli1 function, we generated stable clones of
BE3 cells expressing wild-type Gli1 (BE3/Gli1), Gli1S84A (BE3/
S84A), Gli1S84E (BE3/S84E), or with the empty vector (BE3/
EV). For Gli1S84E, Ser84 was mutated into glutamine to mimic
constitutive phosphorylation of Gli1 at Ser84. We found that
with similar Gli1 expression levels, BE3/S84E bore much higher
Gli1 transcriptional activity and mRNA levels of Gli1 target genes
among all the stable clones (Figures 5A and 5B). Consistently,
the immunofluorescence staining showed that the level of
nuclear Gli1 was much higher in BE3/S84E cells than BE3/Gli1
and BE3/S84A (Figure 5C). To further confirm that the functional
difference was due to the mutations of Gli1, we treated these
cells with TNF-a alone or together with rapamycin and found
that TNF-a markedly induced the Gli1 transcriptional activity in
BE3/Gli1, which was inhibited by cotreatment of rapamycin,
but did not affect the Gli1 activity in BE3/S84E and BE3/S84A
(Figure S5A). The results suggest that both S84E and S84A
mutants were insensitive to TNF-a stimulation. The immunofluo-
rescence staining further showed that TNF-a could enhance Gli1
nuclear localization in BE3/Gli1 cells but not in BE3/S84E or BE3/
S84A cells (Figures 5C and S5B). Moreover, the p-Gli1S84 level
also increased with TNF-a stimulation but gradually decreased
with increased rapamycin dose (Figure S5C). Taken together,
TNF-a-stimulated S84 phosphorylation increases Gli1 nuclear
localization and transcriptional activity, and S84E and S84A
mutants, mimicking phosphorylated and nonphosphorylated
Gli1, respectively, are no longer sensitive to TNF-a.
Many reports have described Gli1 as an oncogene (Jiang and
Hui, 2008; Ng and Curran, 2011); hence, we investigated the
relationship between Gli1 phosphorylation and its tumorigenic
functions. Gli1S84E and wild-type Gli1 but not Gli1S84A
increased cell proliferation (Figure S5D). The Gli1S84E stable
clones also exhibited the highest level of colony formation
activity in soft-agar assay (Figure S5E). BE3/S84E exhibited
much higher invasive ability than BE3/Gli1 and BE3/S84A (Fig-
ure S5F). These results support that the phosphorylation of Gli1
at Ser84 enhances Gli1 function. To further address why the380 Cancer Cell 21, 374–387, March 20, 2012 ª2012 Elsevier Inc.wild-type Gli1 did not show strong biological activities in Figures
S5E–S5F,we treated the BE3/Gli1 stable clonewith TNF-a. Inter-
estingly, we observed increased cell proliferation, anchorage-
independent growth, and invasion (Figures S5G–S5I). Notably,
TNF-a did not affect the BE3/S84E and BE3/S84A stable cells
(Figures S5G–S5I). Therefore, the TNF-a/mTOR pathway
promotes Gli1 function mostly via the Gli1 Ser84 phosphoryla-
tion. Furthermore, we tested the tumorigenicity of these cells by
subcutaneously injecting them into the nude mice. Consistent
with our in vitro data, BE3/S84E had the strongest tumorigenicity
among all stable cells. Whereas BE3/Gli1 also led to tumor
growth in nude mice, the tumors were smaller than those from
BE3/S84E. BE3/EV and BE3/S84A induced only small tumor
formation (Figures 5D and S5J). All these data indicated that
Gli1 Ser84 is a key site for Gli1 activity, and its phosphorylation
by S6K1 enhances Gli1 function as an oncogene.
It has been reported that without HH ligand stimulation, Gli1
function is inhibited by SuFu (Cheng and Yue, 2008). We there-
fore investigated whether Gli1 Ser84 phosphorylation affects
its binding with SuFu. A co-immunoprecipitation experiment
showed that the interaction between SuFu and Gli1 was mark-
edly decreased in BE3/S84E compared with BE3/Gli1 and
BE3/S84A (Figure 5E), which suggested that the Ser84 phos-
phorylation in Gli1 possibly reduced its binding to SuFu.
Similarly, SuFu strongly interacted with exogenous Gli1WT and
Gli1S84A but only weakly with Gli1S84E (Figure S5K). Further-
more, both TNF-a treatment and S6K1 ectopic expression
decreased the binding between SuFu and Gli1, which was
fully reversed by rapamycin administration (Figure 5F). Taken
together, TNF-a/S6K1-induced phosphorylation of Gli1Ser84
attenuates SuFu-mediated Gli1 inhibition.
S6K1 and Gli1 Are Positively Correlated in Human
Tumor Tissues
To investigate the significance of Gli1 regulation by S6K1 in
human EAC tissues, we first validated suitability by immunohis-
tochemistry (IHC) of the anti-Gli1 antibody that we would use,
Figure 5. Functional Effects of S6K1-mediated Gli1 Phosphorylation
(A) Gli1 protein levels and Gli reporter activity in BE3 parental cells and the stable clones established from BE3 parental cells. EV, empty vector; S84A, alanine
mutant of Gli1 Ser84; S84E, glutamine mutant of Gli1 Ser84. Error bars represent SD (n = 3).
(B) The mRNA levels of the Gli1 target genes in BE3 parental cells and stable clones were examined through real-time PCR and normalized to the level of ACTIN.
Error bars represent SD (n = 3).
(C) Immunofluorescent analysis of Gli1 in the BE3 stable clones. Scale bar = 100 mm for original picture and 25 mm for inset. DAPI was used to stain nuclei.
(D) In vivo tumorigenesis assay of the stable clones in nude mice. BE3 stable cells (1 3 105) were subcutaneously injected into the right flank of nude mice,
and tumor volume was measured and calculated using the formula l3w2, where l is the longest diameter and w is the shortest diameter. Error bars represent SD
(n = 5).
(E) Interactions between Gli1 and SuFu in the stable clones through IP-western analysis.
(F) Endogenous interactions between Gli1 and SuFu in BE3 cells with the treatment of TNF-a (5 ng/ml) or ectopic expression of S6K1 with or without rapamycin
(50 nM).
See also Figure S5.
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S6K1-Mediated Activation of Gli1even though it had been used for IHC before (DiMarcotullio et al.,
2006; Fukaya et al., 2006). Consistent with a previous report
(Kolterud et al., 2009), the staining in normal mouse colon
tissues using this antibody showed that the Gli1 signal (brown
color indicated by the arrows) is mainly localized in stromal cells
(Figure S6A, left panel). Furthermore, western blot analysis of
EAC cell lines using this antibody showed a single band at
about 150 kDa (Figure S6B), which is consistent with the Gli1
molecular weight. When Gli1 was knocked down, the signal
detected by the antibody concomitantly decreased compared
with that from the parental or control siRNA-transfected cells
(Figure S6C). This antibody was raised against amino acids
781–1080 of Gli1, and the Gli1 staining was completely blocked
by a GST-Gli1 fragment containing amino acids 501–1160
but not by the fragment containing amino acids 1–500 (Fig-
ure S6D). Therefore, this anti-Gli1 antibody is applicable for
IHC experiment.We then evaluated the levels of Gli1 and p-S6K1 in 107 EAC
tissue specimens by IHC (Figures 6A and 6B). Expression of
both proteins was found in most cases. Eighty out of the 107
for p-S6K1 (74.8%) and 87 of the 107 (81.3%) for Gli1 were posi-
tive (Figure 6A), and there was a strong correlation between the
levels of p-S6K1 and Gli1 (Figure 6C). We also collected 15
samples from rat Barrett’s esophagus models (Yen et al., 2008)
and found that there were no p-S6K1 or Gli1 signals in normal
esophageal squamous cells but observed strong signals of
both p-S6K1 and Gli1 in three of five BE and three of five EAC
tissue samples (Figure S6E). Together, these data further
support the notion that the activation of mTOR/S6K1 and Gli1
pathways is involved in the transformation of esophagus. To
ensure the Gli1S84 phosphorylation also exists in human EAC
tumor tissues, we first tested the applicability of the anti-p-
Gli1S84 antibody for IHC. We found that the staining of p-Gli1
could be blocked by phosphorylated Gli1 peptide used forCancer Cell 21, 374–387, March 20, 2012 ª2012 Elsevier Inc. 381
Figure 6. Correlations between p-S6K1T389 and
Gli1 or p-Gli1S84 in EAC
(A) Statistic analysis of immunohistochemistry (IHC)
staining of Gli1 and p-S6K1 from human EAC tissues.
(B) Representative IHC staining results for Gli1 and
p-S6K1 in human EAC tissues. Scale bar = 50 mm.
(C) Statistic analysis for Gli1 and p-S6K1 correlation from
the IHC staining results in human EAC tissues.
(D) Representative IHC staining results for p-Gli1 or
p-S6K1 in human EAC tissue microarray. Scale bar =
50 mm.
(E) Statistic analysis for Gli1 and p-S6K1 correlation from
the IHC staining results in human EAC tissue microarray.
(F) Statistic analysis for p-Gli1 and p-S6K1 correlation
from the IHC staining results in human EAC tissue micro-
array.
(G) Statistic analysis for p-Gli1 and p-S6K1 correlation
in the Gli1 positive subpopulation of human EAC tissue
microarray.
See also Figure S6.
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peptide (Figure S6F). Moreover, using the same set of mouse
colon tissues used above, we could not detect any signal of
p-S6K1 and, as expected, the signal of p-Gli1 is also negative
(Figure S6A, middle and right panels). Therefore, the p-Gli1 anti-
body is applicable for IHC. We then examined the Gli1, p-Gli1,
and p-S6K1 in human EAC tissue microarray (n = 70), and the
result again showed that there was a strongly positive correlation
between p-S6K1 and Gli1 or p-Gli1 (Figures S6G and 6D–6F). All
p-Gli1-positive tissues are also Gli1-positive, and among the
Gli1-positive tissues, there is also a strong positive correlation
between p-Gli1 and p-S6K1 (Figure 6G). Thus, the phosphoryla-
tion of Gli1 also exists in human EAC tumor tissues. Additionally,
using human tissue microarray with multiple cancer types, we
found a positive correlation between p-S6K1 and Gli1 (Figures
S6H and S6I), suggesting that the regulation of Gli1 by S6K1
might be not limited to EAC and is worthwhile to be tested in
multiple kinds of cancers in the future.
A Combination Therapy that Targets Both Canonical HH
and mTOR/S6K1 Pathways in EAC Cells Provides Better
Therapeutic Effects
Consistent with the previous reports (Berman et al., 2003; Sims-
Mourtada et al., 2006), we detected the activated form of SHH
protein, the amino terminal domain of SHH (SHH-N; Ng and382 Cancer Cell 21, 374–387, March 20, 2012 ª2012 Elsevier Inc.Curran, 2011), in the EAC cell lines (Figure 7A).
In addition, SHH treatment dramatically in-
creased expression of Gli reporter (Figure S7A)
and Gli1 target genes (Figure 7B). Hence, the
EAC cell lines exhibit activated canonical HH
pathway. Because our data have shown that
in EAC cell lines mTOR/S6K1-mediated Gli1
activation is SMO-independent, we speculated
that mTOR/S6K1/Gli1 should enhance the
resistance of EAC cells to SMO inhibitors. As
expected, the IC50 value of cyclopamine or
GDC-0449 in BE3/S84E was much higher than
that for BE3/EV, BE3/Gli1, and BE3/S84A (Fig-ure 7C). Moreover, TNF-a treatment increased the resistance
of BE3/Gli1, but not BE3/S84A, to cyclopamine or GDC-0449
(Figure 7D), suggesting that Gli1S84 phosphorylation enhances
cell resistance to SMO inhibitors. Then, we examined whether
a combination of inhibitors of HH and mTOR pathways would
be more effective for these EAC cell lines. To avoid the killing
effect of rapamycin, we first determined that 10 nM rapamycin
was sufficient to inhibit the activation of S6K1 in BE3 cells but
did not significantly inhibit cell viability (Figure S7B). Thus, we
used 10 nM rapamycin for all subsequent experiments. We
found that rapamycin treatment enhanced the efficacy of cyclop-
amine or GDC-0449 in the EAC cell lines (Figure 7E). Moreover,
knock-down of SMO also inhibited cell viability, and rapamycin
treatment further enhanced the inhibitory effect (Figure S7C).
Interestingly, the effects of rapamycin on SMO inhibitors existed
in BE3/Gli1 cells but not in BE3/S84E cells (Figure 7F). Therefore,
the mTOR inhibitor could enhance SMO inhibitor effects in vitro
through eliminating the phosphorylation of Gli1S84. For further
examination of the crosstalk of mTOR and HH pathways in vivo,
we performed an in vivo combination therapy using GDC-0449
and another mTOR inhibitor, RAD-001, which is widely used
in combination with other antitumor drugs in clinical trials
(Piguet et al., 2011; Price et al., 2010; Quek et al., 2011). We
subcutaneously inoculated mice with BE3 cells and treated
them with GDC-0449, RAD-001, or both and found that though
Cancer Cell
S6K1-Mediated Activation of Gli1low dose RAD001 did not inhibit tumor growth, it enhanced the
tumor-inhibitory effect of GDC-0449 (Figure 7G). Therefore, the
combination of the inhibitors targeting the two pathways could
produce better efficacy for targeted therapy.
SMO-Independent Activation of Gli1 by AKT and ERK
Requires mTOR/S6K1
It has been reported that AKT and MAPK/ERK also activate HH
pathway in a SMO-independent manner. Interestingly, AKT
and ERK can activate the mTOR/S6K1 pathway by inhibiting
the TSC1/2 complex (Lee et al., 2007a; Ma et al., 2005; Ozes
et al., 2001). This prompted us to test if themTOR/S6K1 pathway
is required for the activation of Gli1 by the two kinases. Through
ectopic expression of AKT or ERK, we found that Gli1 activity
increased, which could be blocked by rapamycin (Figure S8).
Moreover, the activation of AKT or ERK also stimulated the phos-
phorylation of S6K1T389 and Gli1Ser84, which was inhibited by
rapamycin (Figure 8A). However, AKT and ERK lost the ability to
induce Gli1 phosphorylation when S6K1 was knocked down
(Figure 8B). Therefore, our results indicated that the mTOR/
S6K1/Gli1 pathway might mediate the previously reported AKT
and ERK-stimulated Gli1 activation (Figure 8C).
DISCUSSION
In this study, we demonstrate a SMO-independent activation of
Gli1 by themTOR/S6K1 pathway, in which activated S6K1 phos-
phorylates Gli1 at Ser84, resulting in its release from SuFu
binding and translocation into the nucleus to activate its target
genes (Figure 8C). We previously reported that the mTOR/
S6K1 pathway facilitates progression from inflammation and
tumorigenesis through upregulation of VEGF, as well as the
subsequent angiogenesis (Lee et al., 2007a). In addition,
TNF-a/mTOR can be activated by chronic inflammation in the
esophagus (Yen et al., 2008). Our work herein further implies
that the mTOR/S6K1 pathway might also promote EAC through
the activation of Gli1. Since Gli1 is known as an oncogene (Ng
and Curran, 2011), our results also provide further evidence to
support the concept that chronic inflammation is an important
stimulator for tumorigenesis of the esophagus (Lambert and
Hainaut, 2007a, 2007b).
The canonical HH pathway is well known to have a tight nega-
tive feedback regulation, which blocks the HH ligands and
inhibits SMO activation through Gli1-promoted transcription of
PTCH and HH interacting protein (Katoh and Katoh, 2006).
When SMO is inactivated, SuFu binds to and inhibits Gli1
function (Katoh and Katoh, 2006). Function-loss-mutation of
SuFu has been shown to result in tumorigenesis due to the aber-
rant activation of the HH pathway (Cheng and Yue, 2008; Lee
et al., 2007b). Therefore, SuFu is an important negative regulator
for the HH pathway and acts as a tumor suppressor. In this
study, we found that the phosphorylation of Gli1 by S6K1
blocked the interaction between SuFu and Gli1, allowing Gli1
to translocate into the nucleus to activate transcription of HH
target genes. Thus, in contrast to the canonical HH pathway,
SMO inhibitors do not seem to affect S6K1-mediatedGli1 activa-
tion, suggesting that the S6K1-mediated release of SuFu from
Gli1 occurs independently of SMO. In fact, SMO inhibitors,
such as cyclopamine and GDC-0449, had little effects on themTOR/S6K1-mediated Gli1 activation. These findings suggest
that the mTOR/S6K1 pathway can act as a positive modulator
to amplify and fuel Gli1 activation to promote tumorigenesis
and disease progression.
The HH pathway has been considered as a therapeutic target
for GI cancers, including esophageal cancers (Lee et al., 2009;
Wiedmann and Caca, 2005). Several SMO inhibitors, including
GDC-0449, are currently being tested in clinical trials, which are
either structurally derived from or functionally similar to cyclop-
amine (Scales and de Sauvage, 2009; Stanton and Peng, 2010).
Our data showed that the administration of GDC-0449 indeed
decreased the EAC tumor size, supporting that GDC-0449 also
couldbeused for treatingEAC (Figure 7G). In this study, however,
we disclose a SMO-independent activation of Gli1 by themTOR/
S6K1 pathway, which cannot be inhibited by SMO inhibitors
but is sensitive to inhibitors of the mTOR pathways. Cotreatment
with mTOR/S6K1 and SMO inhibitors, RAD001 and GDC-0449,
indeed showed better inhibitory effects on tumor growth in vivo
than did single drug treatment. Therefore, our results strongly
suggest that a combination of inhibitors targeting the two path-
ways may be a more effective strategy to treat EAC.
In addition, through the immunostaining analysis of human
EAC tissues, we found that in about 40% (28/70) of patients, all
of the p-Gli1, Gli1, and p-S6K1 were positive, suggesting that
these patients may bear both canonical HH pathway and
mTOR/S6K1-mediatedSMO-independentGli1activation.Based
on the current study, we would predict that this population of
patientsmaynot have full response toGDC-0449 treatment alone
but could benefit from the proposed cotreatment of inhibitors
targeting both the mTOR and HH pathways. Therefore, a prese-
lection procedure might be required for the patients before
receiving the SMO inhibitors to determine whether the cotreat-
ment strategy should be applied. It is worthwhile to mention
that many inhibitors targeting these two pathways are being
tested in clinical trials, such as GDC-0449 and IPI-926, targeting
the HH pathway (Stanton and Peng, 2010), and RAD001 and
AP23573, targeting the mTOR pathway (Konings et al., 2009).
Thus, exploring a vast array of possible therapeutic combinations
will be useful to simultaneously target these pathways.
Although SMO inhibitors are known to inhibit several types of
cancer and have shown hopeful tumor-inhibitory effects, the
development of resistance due to the constitutive activation
mutation of SMO or overactivation of PI3K/AKT pathway has
been reported (Metcalfe and de Sauvage, 2011). Buonamici
et al. further showed that the resistance of medulloblastoma to
SMO inhibitors could be decreased through a combination of
SMO and PI3K/AKT inhibitors (Buonamici et al., 2010). Interest-
ingly, PI3K/AKT and RAS/MEK/ERK have been also found to
activate Gli1 in a SMO-independent manner (Katoh and Katoh,
2009b; Seto et al., 2009; Stecca et al., 2007), though the mech-
anisms are not well understood. Because AKT and ERK can acti-
vate themTOR/S6K1 pathway (Ma et al., 2005; Ozes et al., 2001)
and activation of Gli1 by AKT or ERK requires S6K1 (Figure 8B),
our finding that S6K1 phosphorylates Gli1 and enhances its
function provides a molecular mechanism not only for mTOR/
S6K1-mediated but also AKT or ERK-induced SMO-indepen-
dent Gli1 activation (Figure 8C). Thus, our results also provide
a potential explanation for the resistance of tumor cells to SMO
inhibitors. Similarly, our study offers a rationale for combiningCancer Cell 21, 374–387, March 20, 2012 ª2012 Elsevier Inc. 383
Figure 7. Effects of mTOR and/or HH Pathway Inhibitors on EAC Cells
(A) The expression of activated SHH (SHH-N) in EAC cell lines and the cell culture medium.
(B) The mRNA levels of Gli1 target genes in EAC cell lines with or without SHH treatment (1 mg/ml) induces the upregulation of. The mRNA levels of Gli1 target
genes are normalized to ACTIN. Error bars represent SD (n = 3).
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Figure 8. AKT and ERK Can Activate Gli1 through mTOR/S6K1 Pathway
(A) The regulation of S6K1 and Gli1 by ectopically expressed AKT or ERK in HeLa cells with or without rapamycin (50 nM).
(B) The influence of S6K1 knock-down on the AKT or ERK-stimulated HH pathway in HeLa cells. Error bars represent SD (n = 3).
(C) Schematic diagram for the canonical HH pathway stimulated by HH ligands and SMO-independent Gli1 activation stimulated by the mTOR/S6K1 pathway.
See also Figure S8.
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for treating EAC.
Taken together, our current study identifies Gli1 as a substrate
for S6K1 and establishes a crosstalk between the mTOR/S6K1
and HH pathways, providing a mechanism for SMO-indepen-
dent Gli1 activation. Our data also suggest that the combination
of the inhibitors to these two pathways has a more potent inhib-
itory effect on the EAC cells than single agent alone. Moreover,
we also found the correlation between p-S6K1 and Gli1 of
multiple cancer types using tissue microarray, indicating that
the combined targeted therapy, targeting both the mTOR/S6K1(C) IC50 of cyclopamine (top two panels) or GDC-0449 (bottom two panels) for th
(D) IC50 of cyclopamine (top two panels) or GDC-0449 (bottom two panels) for th
(n = 4).
(E) IC50 of cyclopamine (top two panels) or GDC-0449 (bottom two panels) for EAC
(F) IC50 of cyclopamine (top two panels) or GDC-0449 (bottom two panels) for the G
SD (n = 4).
(G) In vivo combination therapy for subcutaneously inoculated tumors from BE3 c
subcutaneously injected into the right flank of nude mice, and the tumor cells we
The vehicle, GDC-0449, RAD001, or combination of GDC-0449 and RAD001, wa
the formula l x w2, where l is the longest diameter and w is the shortest diamete
See also Figure S7.and HH pathways, may be effective for treatment of EAC, as
well as other cancers.
EXPERIMENTAL PROCEDURES
Human Tissues
Human EAC specimens for immunohistochemistry were obtained retrospec-
tively from patients undergoing complete esophageal surgical resection, as
primary treatment, at MD Anderson Cancer Center (MDACC) between January
1986 and December 1997. The specimen collection was conducted in accor-
dance with the protocols approved by the Institutional Review Board at MD
Anderson Cancer Center, and written informed consent was obtained frome Gli1 stable clones. Error bars represent SD (n = 4).
e Gli1 stable clones with existence of TNF-a (5 ng/ml). Error bars represent SD
cells pretreated with rapamycin (Rapa, 10 nM). Error bars represent SD (n = 4).
li1 stable clones with rapamycin (Rapa, 50 nM) treatment. Error bars represent
ells using GDC-0449 (50 mg/kg) or RAD001 (10 mg/kg). BE3 cells 13 106 were
re allowed to grow for 10 days (the arrow) before initiation of drug treatment.
s orally administrated, qd. The tumor volume measured and calculated using
r. Error bars represent SD (n = 5).
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S6K1-Mediated Activation of Gli1patients in all cases at time of enrollment. Themultiple tissuemicroarrays were
purchased fromUSBiomax, Inc. (BC00112 andMTU241; Rockville,MD, USA).
Immunoprecipitation, Immunoblotting, and In Vitro Kinase Assays
Immunoprecipitation and immunoblotting were performed as previously
described (Lee et al., 2007a). For in vitro kinase assay, the BL21 competent
cells were transformed with pGEX-6P-1, pGEX-6P-1-S6, pGEX-6P-1-Gli1F1,
or pGEX-6P-1-Gli1F2 vectors. After overnight growth, the cells were lysed,
and the target proteins were purified using the GST antibody crosslinked
agarose beads (Thermo Scientific, Hudson, NH, USA) in accordance with the
manufacturer’s instruction. In addition, 90% confluent BE3 cells were trans-
fected with HA-S6K1, HA-S6K1T389E, HA-S6K1T389A, or HA-S6K1K100R,
and 24 hr after transfection, the cells were lysed and immunoprecipitated
with anti-HA antibody. Purified GST protein or GST fusion proteins were incu-
bated with purified HA-S6K1 or HA-S6K1 mutants in the presence of 50 mM
ATP in a kinase buffer for 30 min at 30C. Reaction products were subjected
to SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and then blotted with phosphor-Thr/Ser antibody.
IC50 Evaluation for Cyclopamine and GDC-0449
Cells were seeded in 96-well plates at the density of 5,000 cells/well. After
overnight growth, the cells were exposed to increasing concentrations,
ranging from 1 nM to 100 mM for cyclopamine or GDC-0449, with or without
10 nM rapamycin, for 48 hr. The concentrations required to inhibit cell growth
by 50% (IC50) were calculated from survival curves.
Rat Model of BE and EAC
The rat model was established as previously described (Yen et al., 2008). The
excised esophageal tissues from normal esophagus, BE, or EAC were fixed in
10% buffered formalin for 24 hr and then transferred to 80% ethanol. The
tissuewas longitudinally divided into slices for immunohistochemistry staining.
Tumorigenicity Assay and Combination Therapy In Vivo
All animal experimentswere approved by the Institutional Animal Care andUse
Committee (IACUC) at MD Anderson Cancer Center. Nude female mice were
housed under standard conditions. For tumorigenicity assay, 1 3 105 BE3
stable cells were subcutaneously injected in right flank. The resulting tumors
were measured with calipers weekly, and tumor volume was determined using
the formula l3 w2, where l is the longest diameter and w is the shortest diam-
eter. For combination therapy, 13 106 BE3 cells were subcutaneously injected
in right flanks of nude mice and allowed to grow for 10 days before drug treat-
ment. GDC-0449 was formulated in MCT (0.5% methylcellulose and 0.5%
Tween 80) and RAD001 in water. GDC-0449 (50 mg/kg) and RAD001
(10 mg/kg) were dosed qd (quaque die (qd) by oral gavage. The tumors
were measured with calipers every 4 days. Data were presented as tumor
volume (mean ± SD). Statistical analysis was done using the Student’s t test
by the program SPSS for Windows.
Statistical Analyses
Statistical analyses were performed with the Student’s t test, Spearman rank
correlation test, or Fisher’s exact test as indicated. A p value of <0.05 was
considered statistically significant. All data analyses were performed using
the program SPSS for Windows.
All other experimental procedures are described in the Supplemental Exper-
imental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2011.12.028.
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